Key facts
- Reesi’s last known valuation is $11.6M (Aug 2025).
- It has raised $1.4M; the latest was Early Stage VC ($1.4M) in Aug 2025.
- Notable investors include Caesar Ventures, GIMIC Ventures, OHA Osnabrück Healthcare Beteiligungs, RoX Health.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Reesi
- ·The full record, as it builds
Funding rounds
No funding rounds for Reesi are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reesi
Operator of an AI-native clinical trial matching platform intended to connect patients and physicians with relevant studies across Europe. The company's platform aggregates fragmented trial data from public and private registries, including proprietary non-public data, and applies AI to structure eligibility criteria and reduce manual screening effort, supports transparent communication between stakeholders, reduces manual screening effort and time, and enables the German oncology ecosystem to access suitable studies more efficiently and make better-informed, patient-centric treatment decisions.
- Sector
- Healthcare
- HQ
- Hamburg, Germany
- Founded
- 2024
- Employees
- 7
- Website
- reesi.de/
- Ownership
- Privately Held (backing)
Reesi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reesi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reesi in its N-PORT filings yet. We sweep new filings monthly.